Drugs / AK104 plus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06832917 | Mar 2025 → Dec 2028 expected | rectal cancer | Wan He | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK104 plus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06832917 ↗ |